Hbv-Hcv / Prophylactic vaccine for hepatitis C and hepatitis B

MARKET

• Approximately 170 million people around the world, i.e., 3 % of the population, are affected

by the hepatitis C virus.

3 to 4 million new cases are diagnosed annually. Currently, there is no vaccine on the

market, and the therapies that make it possible today to cure 40 to 80 % of sufferers

experience side effects, and their price renders them unaffordable for most people.

Worldwide sales of hepatitis C therapies were $4.1B in 2012 with a growth rate in this

market at 11%, especially in Asian countries.

TECHNOLOGY DESCRIPTION

• The technology is an HCV-HBV chimeric protein containing the entire E1 and E2 sequence

of hepatitis C assembled in viral particles that are easy to purify.

These particles are produced in stable CHO cells and induce high titer specific antibodies

for HCV and HBV in adequate models.

COMPETITIVE ADVANTAGES

• Protects against several genotypes

• Prophylactic treatment

• Complementary to the HBV vaccination